The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor
Open accessAbstract
A boost for CAR–T cells: Chimeric antigen receptor (CAR)–T cell immunotherapy has been highly successful for treating certain blood cancers. Yet this approach has been a challenge for solid tumors, in part because it is difficult to target functional engineered T cells to the tumor site. Ma et al. designed a vaccine strategy to improve the efficacy of CAR–T cells by restimulating the CAR directly within the native lymph node microenvironment (see the Perspective by Singh and June). Injected “amph-ligand” vaccines promoted synthetic antigen presentation and led to CAR–T cell activation, expansion, and increased tumor killing. The system could potentially be applied to boost any CAR–T cell. Science , this issue p. 162 ; see also p. 119
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
How to calculate sample size in animal studies?
Charan, J., & Kantharia, N. D. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119726 · Cited by 1,881
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337
Sotillo, E., Barrett, D. M., Black, K. L., Bagashev, A., Oldridge, D., Wu, G., Sussman, R., Lanauze, C., Ruella, M., Gazzara, M. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1020 · Cited by 1,254
Engineered T cells: the promise and challenges of cancer immunotherapy
Fesnak, A. D., June, C. H., & Levine, B. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.97 · Cited by 1,074
Structure-based programming of lymph-node targeting in molecular vaccines
Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Van Egeren, D. S., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 943
Self-citationThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Cited by
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Melief, C. J. M., van Hall, T., Arens, R., Ossendorp, F., & van der Burg, S. H. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80009 · Cited by 1,164
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 882
Self-citationRecent advances and discoveries in the mechanisms and functions of CAR T cells
Larson, R. C., & Maus, M. V. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00323-z · Cited by 852
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Navigating CAR-T cells through the solid-tumour microenvironment
Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 551
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512
CAR T therapy beyond cancer: the evolution of a living drug
Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. (2023) · Nature · doi:10.1038/s41586-023-06243-w · Cited by 504
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity
Guo, Y., Xie, Y.-Q., Gao, M., Zhao, Y., Franco, F., Wenes, M., Siddiqui, I., Bevilacqua, A., Wang, H., Yang, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00940-2 · Cited by 440
Supramolecular cancer nanotheranostics
Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00011f · Cited by 411
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Wagner, J., Wickman, E., DeRenzo, C., & Gottschalk, S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 380
Nanomaterials for T-cell cancer immunotherapy
Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 306
A second-generation M1-polarized CAR macrophage with antitumor efficacy
Lei, A., Yu, H., Lu, S., Lu, H., Ding, X., Tan, T., Zhang, H., Zhu, M., Tian, L., Wang, X., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01687-8 · Cited by 299
Li, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
Engineered cellular immunotherapies in cancer and beyond
Finck, A. V., Blanchard, T., Roselle, C. P., Golinelli, G., & June, C. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01765-8 · Cited by 269
Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02760-3 · Cited by 267
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Self-citationCAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
Peptides for Vaccine Development
Hamley, I. W. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c01238 · Cited by 104
Sánchez-Paulete, A. R., Mateus-Tique, J., Mollaoglu, G., Nielsen, S. R., Marks, A., Lakshmi, A., Khan, J. A., Wilk, C. M., Pia, L., Baccarini, A., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-1075 · Cited by 98
Engineering Nano‐Therapeutics to Boost Adoptive Cell Therapy for Cancer Treatment
Zheng, C., Zhang, J., Chan, H. F., Hu, H., Lv, S., Na, N., Tao, Y., & Li, M. (2021) · Small Methods · doi:10.1002/smtd.202001191 · Cited by 61
Rust, B. J., Kean, L. S., Colonna, L., Brandenstein, K. E., Poole, N. H., Obenza, W., Enstrom, M. R., Maldini, C. R., Ellis, G. I., Fennessey, C. M., et al. (2020) · Blood · doi:10.1182/blood.2020006372 · Cited by 58
RetractedCurrent advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
Zhou, H., Ma, Y., Liu, F., Li, B., Qiao, D., Ren, P., & Wang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1255799 · Cited by 46
Green, J. J. (2021) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37041 · Cited by 24
Metadata
- Authors
- Ma, L., Dichwalkar, T., Chang, J. Y. H., Cossette, B., Garafola, D., Zhang, A. Q., Fichter, M., Wang, C., Liang, S., Silva, M., Kumari, S., Mehta, N. K., Abraham, W., Thai, N., Li, N., Wittrup, K. D., & Irvine, D. J.
- Venue
- Science
- Published
- 2019-07-12
- Volume
- 365
- Issue
- 6449
- Pages
- 162-168
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2957969985
- Cited by
- 439
- References
- 29
- FWCI
- 17.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.